Today's Market Driven by Key Factors: New Coverage on Genomic Health, Eli Lilly, Quiksilver, Dominion Diamond and Vermillion

NEW YORK, December 15, 2014 /PRNewswire/ --

Moments ago, Realtime Equities released new analyst updates concerning several important developing situations. Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links at the bottom.

--

Analyst Update: Study Results, FDA Approval, Quarterly Earnings, and Director Appointment
Reviewed  by:  Rohit  Tuli,  CFA®

The U.S. markets on Friday plummeted as the price of crude oil continued its decline and dipped to $57.81 per barrel from $107.95 per barrel as on June 20, 2014. The Dow Jones Industrial Average finished at 17,280.83, down 1.79%, the NASDAQ Composite closed at 4,653.60, down 1.16% and the S&P 500 ended 1.62% lower at 2,002.33. The market was further hit as the International Energy Agency slashed its oil production growth forecast by 230,000 barrels per day. The Asian stock markets ended on a mixed note after two contrasting pieces of economic data surfaced from China. China's industrial output for the month of November 2014 increased by a less-than-expected 7.2% YoY, but retail sales rose 11.7%, beating forecasts. China's fixed-asset investment increased 15.8% in the first 11 months of the year, in line with expectations. The European markets ended the day in red, led by gloomy global crude demand and a weak Chinese economic data.

Genomic Health, Inc. (Genomic Health) announced positive results  from the second large clinical validation study of Oncotype DX in patients with a pre-invasive form of breast cancer known as DCIS (ductal carcinoma in situ). The study reconfirmed that the Oncotype DX DCIS Score is a strong predictor of local recurrence, which could be either invasive breast cancer or DCIS. Click on the link below to find out more about this latest breakthrough.  

Eli Lilly and Company's (Eli Lilly) Cyramza drug has received the approval from U.S. Food and Drug Administration for the treatment of non-small cell lung cancer, the most common type of lung cancer. Eli Lilly's Cyramza was earlier approved for treatment of patients with advanced or metastatic gastric cancer. Find out more about Eli Lilly's Cyramza and the latest FDA approval by clicking on the report below.

BRT Realty Trust (BRT) was among the biggest volume gainers on NYSE on Friday, December 12, with as many as 638,820 shares changing hands during the session - a 2,229.7% increase over its 30-day average volume. The sharp increase in volume followed BRT's fourth quarter fiscal 2014 results on Thursday. Click on the link below to know view BRT's performance in Q4 FY 2014.

Shares in Dominion Diamond Corp (Dominion Diamond) jumped over 3% to close at near its 52-week high after reporting better-than-expected third quarter fiscal 2015 results. Dominion Diamond reported net income for the quarter of $25.5 million or $0.30 per share, versus a net loss of $4.8 million, or $0.06 per share, in the year ago period. Click on the report below to view a detailed coverage of Dominion Diamond's Q3 FY 2015 results.

Vermillion, Inc. (Vermillion) has added two new members to its Board of Directors -- Veronica G. H. Jordan, Ph.D., and David R. Schreiber. This takes the Company's total number of directors to eight, seven of whom are independent.  Click on the report below to find out more about the two new faces on Vermillion's Board.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

GHDX  ResearchReport: ( http://get.realtimeequities.com/pdf/?c=Genomic%20Health&d=15-Dec-2014&s=GHDX ),

LLY ResearchReport: ( http://get.realtimeequities.com/pdf/?c=Eli%20Lilly&d=15-Dec-2014&s=LLY ),

BRT Research Report: ( http://get.realtimeequities.com/pdf/?c=BRT%20Realty%20Trust&d=15-Dec-2014&s=BRT ),

DDC Research Report: ( http://get.realtimeequities.com/pdf/?c=Dominion%20Diamond&d=15-Dec-2014&s=DDC ),

VRML Research Report: ( http://get.realtimeequities.com/pdf/?c=Vermillion&d=15-Dec-2014&s=VRML ).

============

--

About  Realtime  Equities  

Tired of missing trades? In a world where information travels at the speed of light, you can't afford to be out of touch. Get an actionable source of information. Find the best opportunities available in real-time. Don't waste time trying to chase the news, get ahead of it with Realtime Equities. We find information as it happens and send it out to our subscribers in our e-alerts. Our focus is to find companies positioned to see upward momentum, delivering alerts to your inbox as the event unfolds in realtime. Join us in our battle to beat the markets, you'll be happy you did.

We are proud to serve professional traders, financial advisors, hedge funds and experience individual investors including some of the top firms on wall-street today. For more information about our service offerings and subscriptions, please visit our website or reach out to our sales staff. Advanced subscription packages are available to qualifying institutional clients and accredited investors, please speak with your account manager to learn more about these custom opportunities.

If you enjoyed today's content, subscribe to our live updates here: ( http://get.realtimeequities.com/updates )

--

Editor  Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance  Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Realtime Equities, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Realtime Equities in this article or report according to the procedures outlined by Realtime Equities. Realtime Equities is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further  Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.realtimeequities.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Realtime Equities